Advertisement

Radiation Therapy as Applied to Prostate Cancer

Clinical, Technical, and Biologic Considerations
  • Naren R. Ramakrishna
  • Theodore L. DeWeese
Part of the Contemporary Cancer Research book series (CCR)

Abstract

Radiation has been used in the treatment of prostate cancer for nearly a century. Following Roentgen’ s discovery of the X-ray in 1895 (96), and the isolation of radium by Pierre and Marie Curie in 1898 (21), several physicians began treating prostate disorders, including prostate cancer, with radiation. In 1910, Paschkis and Tittinger inserted radium into the prostatic urethra with a cystoscope in what appears to be the first documented use of radiation for prostate cancer. Not long after, Hugh Young from Johns Hopkins reported a relatively large usage of treating prostate cancer patients with urethral and rectal radium “applicators” (127). These early studies revealed that radiation applied in this crude fashion could improve a patient’s local symptoms and eliminate prostate cancer, but was difficult to perform and uncomfortable for the patient. In 1928, Barringer was one of the first to report on the use of externally-delivered low-energy kilovoltage radiation for prostate cancer (5). Dosimetric considerations were not well understood, and patients were treated until their skin turned red. These types of low-energy radiation machines were used until cobalt machines became available and provided the first opportunity to treat more deeply seated tumors in the body. The first reported series of prostate cancer patients treated with cobalt-60 therapy, by George et al. in 1965, focused on patients with unresectable disease (40). It was not until the development of the megavoltage linear accelerator at Stanford University in the late 1950s (62) and the pioneering work of Bagshaw, Kaplan, Del Ragato, and others, that the modern era of radiation therapy for prostate cancer began revealing the possibility of radiation curability in this disease (4,26). Drawing from these beginnings, we now use three-dimensional conformal plans to drive high-energy accelerators with sophisticated dynamic shielding in order to treat the prostate with a high dose of radiation while sparing the surrounding normal tissues.

Keywords

Prostate Cancer Gene Therapy Prostate Cancer Cell Prostate Cancer Patient Prostate Cancer Cell Line 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Aaltomaa, S., et al. 1999. Prognostic value and expression of p21(wafl/cipl) protein in prostate cancer. Prostate 39: 8–15.PubMedCrossRefGoogle Scholar
  2. 2.
    Akimoto, T., et al. 1999. Association of increased radiocurability of murine carcinomas with low constitutive expression of P21 WAF1/CIP1 protein. Mt. J. Rad. Oncol. Biol. Phys. 44: 413–419.CrossRefGoogle Scholar
  3. 3.
    Asgari, K., et al. 1997. Inhibition of the growth of pre-established subcutaneous tumor nodules of human prostate cancer cells by single injection of the recombinant adenovirus p53 expression vector. Int. J. Cancer 71: 377–382.PubMedCrossRefGoogle Scholar
  4. 4.
    Bagshaw, M. A., H. S. Kaplan, and R. H. Sagerman. 1965. Linear accelerator supervoltage radiotherapy. VII. Carcinoma of the prostate. Radiology 85: 121–129.PubMedGoogle Scholar
  5. 5.
    Barringer, B. S. 1928. Phases of the pathology, diagnosis and treatment of cancer of the prostate. J. Urol. 407–411.Google Scholar
  6. 6.
    Batterman, J. J. 1981. The Clinical Application of Fast Neutrons: the Amsterdam Experience. Amsterdam: Rodipi.Google Scholar
  7. 7.
    Bernhard, E. J., et al. 1998. Inhibiting Ras prenylation increases the radiosensitivity of human tumor cell lines with activating mutations of ras oncogenes. Cancer Res. 58: 1754–1761.PubMedGoogle Scholar
  8. 8.
    Boehm, T., et al. 1997. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390: 404–407.PubMedCrossRefGoogle Scholar
  9. 9.
    Bolla, M., et al. 1997. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N. Engl. J. Med. 337: 295–300.PubMedCrossRefGoogle Scholar
  10. 10.
    Bookstein, R., et al. 1993. p53 is mutated in a subset of advanced-stage prostate cancers. Cancer Res. 53: 3369–3373.Google Scholar
  11. 11.
    Bostwick, D. G. and J. W. Aquilina. 1996. Prostatic intraepithelial neoplasia (PIN) and other prostatic lesions as risk factors and surrogate endpoints for cancer chemoprevention trials. J. Cell Biochem. Suppl. 25: 156–164.PubMedCrossRefGoogle Scholar
  12. 12.
    Bowen, C., S. Spiegel, and E. P. Gelmann. 1998. Radiation-induced apoptosis mediated by retinoblastoma protein. Cancer Res. 58: 3275–3281.PubMedGoogle Scholar
  13. 13.
    Bristow, R. G., S. Benchimol, and R. P. Hill. 1996. The p53 gene as a modifier of intrinsic radiosensitivity: implications for radiotherapy. Radiother. Oncol. 40: 197–223.PubMedCrossRefGoogle Scholar
  14. 14.
    Chapman, J., et al. 1973. Chemical radioprotection and radiosensitization of mammalian cells growing in vitro. Radiat. Res. 56: 291–306.PubMedCrossRefGoogle Scholar
  15. 15.
    Chi, S. G., et al. 1997. Frequent alteration of CDKN2 (p16(INK4A)/MTS1) expression in human primary prostate carcinomas. Clin. Cancer Res. 3: 1889–1897.PubMedGoogle Scholar
  16. 16.
    Chuba, P. J., et al. 1996. Hip stiffness following mixed conformal neutron and photon radiotherapy: a dose-volume relationship. Int. J. Radiat. Oncol. Biol. Phys. 35: 693–699.PubMedCrossRefGoogle Scholar
  17. 17.
    Critz, F. A., et al. 1998. Simultaneous radiotherapy for prostate cancer: 125I prostate implant followed by external beam radiation. Cancer J. Sci. Am. 4: 359–363.PubMedGoogle Scholar
  18. 18.
    Critz, F. A., R. S. Tarlton, and D. A. Holladay. 1995. Prostate specific antigen-monitored combination radiotherapy for patients with prostate cancer. I-125 implant followed by external beam radiation. Cancer. 75: 2383–2391.PubMedCrossRefGoogle Scholar
  19. 19.
    Culig, Z., et al. 1995. Activation of the androgen receptor by polypeptide growth factors and cellular regulators. World J. Urol. 13: 285–289.PubMedCrossRefGoogle Scholar
  20. 20.
    Culig, Z., et al. 1995. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor and epidermal growth factor. Eur. Urol. 27 (Suppl. 2): 45–47.PubMedGoogle Scholar
  21. 21.
    Curie, M. S. 1904. Recherches sur les substances radioactives, in These presentee a la Faculte des Sciences de Paris pour obtenir le grade de docteur es sciences physiques, 2nd ed. Gauthier-Villas, Paris.Google Scholar
  22. 22.
    Dahut, W., et al. 1998. Strontium-89 and estramustine: delaying treatment failure in hormone-refractory prostate cancer. J. Clin. Oncol. 17 (Annual Meeting Report).Google Scholar
  23. 23.
    D’Amico, A.V., et al. 1998. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280: 969–974.PubMedGoogle Scholar
  24. 24.
    Dattoli, M., et al. 1996. 103Pd brachytherapy and external beam irradiation for clinically localized, high-risk prostatic carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 35: 875–879.Google Scholar
  25. 25.
    Del Regato, J. 1968. Radiotherapy for carcinoma of the prostate. A report from the Committee for the Cooperative Study of Radiotherapy for Carcinoma of the Prostate. Penrose Cancer Hospital: Colorado Springs, CO.Google Scholar
  26. 26.
    Del Regato, J. A. 1967. Radiotherapy in the conservative treatment of operable and locally inoperable carcinoma of the prostate. Radiology 88: 761–766.PubMedGoogle Scholar
  27. 27.
    DeWeese, T., et al. 1998. Inactivation of GSTPI genes provides a survival advantage following oxidative DNA damage in human prostate cancer cells. Proc. Am. Assoc. Cancer Res. 39: 466.Google Scholar
  28. 28.
    DeWeese, T. L., et al. 1998. Mouse embryonic stem cells carrying one or two defective Msh2 alleles respond abnormally to oxidative stress inflicted by low-level radiation. Proc. Natl. Acad. Sci. USA 95: 11,915–11, 920.Google Scholar
  29. 29.
    DeWeese, T. L., et al. 1998. Sensitivity of human prostatic carcinoma cell lines to low dose rate radiation exposure. J. Urol. 159: 591–598.PubMedCrossRefGoogle Scholar
  30. 30.
    Dinges, S., et al. 1998. High-dose rate interstitial with external beam irradiation for localized prostate cancer-results of a prospective trial. Radiother. Oncol. 48: 197–202.PubMedCrossRefGoogle Scholar
  31. 31.
    Dische, S. 1983. Clinical trials with hypoxic cell sensitizers-the European experience. Prog. Clin. Biol. Res. 293–303.Google Scholar
  32. 32.
    Dong, J. T., et al. 1995. KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2. Science 268: 884–886.PubMedCrossRefGoogle Scholar
  33. 33.
    Elgamal, A. A., M. J. Troychak, and G. P. Murphy. 1998. ProstaScint scan may enhance identification of prostate cancer recurrences after prostatectomy, radiation, or hormone therapy: analysis of 136 scans of 100 patients. Prostate 37: 261–269.PubMedCrossRefGoogle Scholar
  34. 34.
    Engels, H. and A. Wambersie. 1998. Relative biological effectiveness of neutrons for cancer induction and other late effects: a review of radiobiological data. Recent results. Cancer Res. 150: 54–87.Google Scholar
  35. 35.
    Forman, J. D., et al. 1996. Comparison of hyperfractionated conformal photon with conformal mixed neutron/photon irradiation in locally advanced prostate cancer. Bull. Cancer Radiother. 83(Suppl.): 101s - 105s.Google Scholar
  36. 36.
    Forman, J. D., et al. 1996. Conformal mixed neutron and photon irradiation in localized and locally advanced prostate cancer: preliminary estimates of the therapeutic ratio. Int. J. Radiat. Oncol. Biol. Phys. 35: 259–266.PubMedCrossRefGoogle Scholar
  37. 37.
    Fu, X. Y., et al. 1998. Restoration of the p16 gene is related to increased radiosensitivity of p16-deficient lung adenocarcinoma cell lines. J. Cancer Res. Clin. Oncol. 124: 621–666.PubMedCrossRefGoogle Scholar
  38. 38.
    Fuks, Z., et al. 1991. The effect of local control on metastatic dissemination in carcinoma of the prostate: long-term results in patients treated with 125I implantation. Int. J. Radiat. Oncol. Biol. Phys. 21: 537–547.PubMedCrossRefGoogle Scholar
  39. 39.
    Furuya, Y., et al. 1995. Androgen ablation-induced programmed death of prostatic glandular cells does not involve recruitment into a defective cell cycle or p53 induction. Endocrinology 136: 1898–1906.PubMedCrossRefGoogle Scholar
  40. 40.
    George, F. W., et al. 1965. Cobalt-60 telecurietherapy in the definitive treatment of carcinoma of the prostate: a preliminary report. J. Urol. 93: 102–109.PubMedGoogle Scholar
  41. 41.
    Giardiello, F. M., et al. 1993. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N. Engl. J. Med. 328: 1313–1316.PubMedCrossRefGoogle Scholar
  42. 42.
    Girinsky, T., et al. 1995. Attenuated response of p53 and p21 in primary cultures of human prostatic epithelial cells exposed to DNA-damaging agents. Cancer Res. 55: 3726–3731.PubMedGoogle Scholar
  43. 43.
    Gorski, D. H., et al. 1998. Potentiation of the antitumor effect of ionizing radiation by brief concomitant exposures to angiostatin. Cancer Res. 58 (24): 5686–5689.PubMedGoogle Scholar
  44. 44.
    Green, N., et al. 1984. Improved control of bulky prostate carcinoma with sequential estrogen and radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 10: 971–976.PubMedCrossRefGoogle Scholar
  45. 45.
    Gu, K., et al. 1996. Overexpression of her-2/neu in human prostate cancer and benign hyperplasia. Cancer Lett. 99: 185–189.PubMedCrossRefGoogle Scholar
  46. 46.
    Hall, E. J., et al. 1998. A preliminary report: frequency of A-T heterozygotes among prostate cancer patients with severe late responses to radiation therapy. Cancer J. Sci. Am. 4: 385–389.PubMedGoogle Scholar
  47. 47.
    Hall, E. J. and D. J. Brenner. 1991. The dose-rate effect revisited: radiobiological considerations of importance in radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 21: 1403–1414.PubMedCrossRefGoogle Scholar
  48. 48.
    Hallahan, D. E., et al. 1995. Spatial and temporal control of gene therapy using ionizing radiation. Nat. Med. 1: 786–791.PubMedCrossRefGoogle Scholar
  49. 49.
    Hanks, G. E., et al. 1996. Conformal technique dose escalation for prostate cancer: biochemical evidence of improved cancer control with higher doses in patients with pretreatment prostate-specific antigen or = 10 NG/ML. Int. J. Radiat. Oncol. Biol. Phys. 35: 861–868.PubMedCrossRefGoogle Scholar
  50. 50.
    Hanks, G. E., et al. 1999. Survival advantage for prostate cancer patients treated with high-dose three-dimensional conformal radiotherapy. Cancer J. Sci. Am. 5: 152–158.PubMedGoogle Scholar
  51. 51.
    Hanna, N. N., et al. 1997. Virally directed cytosine deaminase/5-fluorocytosine gene therapy enhances radiation response in human cancer xenografts. Cancer Res. 57: 4205–4209.PubMedGoogle Scholar
  52. 52.
    Hawkins, V., et al. 1999. PEDB: the prostate expression database. Nucleic Acids Res. 27: 204–208.PubMedCrossRefGoogle Scholar
  53. 53.
    Heidenberg, H. B., et al. 1995. Alteration of the tumor suppressor gene p53 in a high fraction of hormone refractory prostate cancer. J. Urol. 154: 414–421.PubMedCrossRefGoogle Scholar
  54. 54.
    Hockel, M., et al. 1996. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res. 56: 4509–4515.PubMedGoogle Scholar
  55. 55.
    Hockel, M., et al. 1993. Tumor oxygenation: a new predictive parameter in locally advanced cancer of the uterine cervix. Gynecol. Oncol. 51: 141–149.PubMedCrossRefGoogle Scholar
  56. 56.
    Holm, H. H., et al. 1983. Transperineal 125 iodine seed implantation in prostatic cancer guided by transrectal ultrasonography. J. Urol. 130: 283–286.PubMedGoogle Scholar
  57. 57.
    Huang, A., et al. 1998. p53 and bc1–2 immunohistochemical alterations in prostate cancer treated with radiation therapy. Urology 51: 346–351.Google Scholar
  58. 58.
    Isaacs, W. B., et al. 1994. Molecular biology of prostate cancer. Semin. Oncol. 21: 514–521.PubMedGoogle Scholar
  59. 59.
    Isaacs, W. B., et al. 1995. Molecular biology of prostate cancer progression. Cancer Surv. 23: 19–32.PubMedGoogle Scholar
  60. 60.
    Jarrard, D. F., et al. 1997. Deletional, mutational, and methylation analyses of CDKN2 (p16/MTS1) in primary and metastatic prostate cancer. Genes Chromosomes Cancer 19: 90–96.PubMedCrossRefGoogle Scholar
  61. 61.
    Joon, D. L., et al. 1997. Supraadditive apoptotic response of R3327-G rat prostate tumors to androgen ablation and radiation. Int. J. Radiat. Oncol. Biol. Phys. 38: 1071–1077.PubMedCrossRefGoogle Scholar
  62. 62.
    Kaplan, H. S. and M. A. Bagshaw. 1957. The Stanford medical linear accelerator. III. Application to clinical problems of radiation therapy. Stanford Med. Bull. 15: 141–151.PubMedGoogle Scholar
  63. 63.
    Kimura, K., et al. 1999. Tumor necrosis factor-alpha sensitizes prostate cancer cells to gamma-irradiation-induced apoptosis. Cancer Res. 59: 1606–1614.PubMedGoogle Scholar
  64. 64.
    Konishi, N., et al. 1997. Genetic changes in prostate cancer. Pathol. Int. 47 (11): 735–747.PubMedCrossRefGoogle Scholar
  65. 65.
    Krasilnikov, M., et al. 1999. Contribution of phosphatidylinositol 3-kinase to radiation resistance in human melanoma cells. Mol. Carcinog. 24: 64–69.PubMedCrossRefGoogle Scholar
  66. 66.
    Kyprianou, N., et al. 1997. bc1–2 over-expression delays radiation-induced apoptosis without affecting the clonogenic survival of human prostate cancer cells. Int. J. Cancer 70: 341–348.Google Scholar
  67. 67.
    Lamb, H. M. and D. Faulds. 1998. Capromab pendetide. A review of its use as an imaging agent in prostate cancer. Drugs Aging 12: 293–304.PubMedCrossRefGoogle Scholar
  68. 68.
    Laramore, G. E., et al. 1993. Fast neutron radiotherapy for locally advanced prostate cancer. Final report of Radiation Therapy Oncology Group randomized clinical trial. Am. J. Clin. Oncol. 16: 164–167.PubMedCrossRefGoogle Scholar
  69. 69.
    Laverdiere, J., et al. 1997. Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 37: 247–252.PubMedCrossRefGoogle Scholar
  70. 70.
    Lawton, C. A., et al. 1996. Results of a phase II trial of external beam radiation with etanidazole (SR 2508) for the treatment of locally advanced prostate cancer (RTOG Protocol 90–20). Int. J. Radiat. Oncol. Biol. Phys. 36: 673–680.PubMedCrossRefGoogle Scholar
  71. 71.
    Lee, W. H., et al. 1994. Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc. Natl. Acad. Sci. USA 91: 11,733–11, 737.Google Scholar
  72. 72.
    Lu, J., C. M. Chuong, and R. B. Widelitz. 1997. Isolation and characterization of chicken beta-catenin. Gene 196: 201–207.PubMedCrossRefGoogle Scholar
  73. 73.
    Mackey, T. J., et al. 1998. bcl-2/bax ratio as a predictive marker for therapeutic response to radiotherapy in patients with prostate cancer. Urology 52: 1085–1090.Google Scholar
  74. 74.
    Mashimo, T., et al. 1998. The expression of the KAI1 gene, a tumor metastasis suppressor, is directly activated by p53. Proc. Natl. Acad. Sci. USA 95: 11,307–11, 311.Google Scholar
  75. 75.
    Mason, K. A. and H. R. Withers. 1977. RBE of neutrons generated by 50 MeV deuterons on beryllium for control of artificial pulmonary metastases of a mouse fibrosarcoma. Br. J. Radiol. 50: 652–657.PubMedCrossRefGoogle Scholar
  76. 76.
    Matsumura, Y., et al. 1997. Increase in radiation sensitivity of human malignant melanoma cells by expression of wild-type p16 gene. Cancer Lett. 115: 91–96.PubMedCrossRefGoogle Scholar
  77. 77.
    Mauceri, H. J., et al. 1998. Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature 394: 287–291.PubMedCrossRefGoogle Scholar
  78. 78.
    Mehta, M. P. 1998. Protection of normal tissues from the cytotoxic effects of radiation therapy: focus on amifostine. Semin. Radiat. Oncol. 8 (4 Suppl. 1): 14–16.PubMedGoogle Scholar
  79. 79.
    Miyakoshi, J., et al. 1997. Increased radiosensitivity of p16 gene-deleted human glioma cells after transfection with wild-type p16 gene. Jpn. J. Cancer Res. 88: 34–38.PubMedCrossRefGoogle Scholar
  80. 80.
    Movsas, B., et al. 1999. Hypoxic regions exist in human prostate carcinoma. Urology 53: 11–18.PubMedCrossRefGoogle Scholar
  81. Munzenrider, J. E. and N. J. Liebsch. 1999. Proton therapy for tumors of the skull base. Strahlenther. Onkol. 175 (Suppl. 2): 57–63.Google Scholar
  82. 82.
    Mydlo, J. H., et al. 1998. An analysis of microvessel density, androgen receptor, p53 and HER- 2/neu expression and Gleason score in prostate cancer. Preliminary results and therapeutic implications. Eur. Urol. 34: 426–432.PubMedCrossRefGoogle Scholar
  83. 83.
    Nielsen, L. L., et al. 1998. Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer. Clin. Cancer Res. 4: 835–846.PubMedGoogle Scholar
  84. 84.
    Nishihara, E., et al. 1997. Retrovirus-mediated herpes simplex virus thymidine kinase gene transduction renders human thyroid carcinoma cell lines sensitive to ganciclovir and radiation in vitro and in vivo. Endocrinology 138: 4577–4583.PubMedCrossRefGoogle Scholar
  85. 85.
    Oshima, M., et al. 1996. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 87: 803–809.PubMedCrossRefGoogle Scholar
  86. 86.
    O’Rourke, D. M., et al. 1998. Conversion of a radioresistant phenotype to a more sensitive one by disabling erbB receptor signaling in human cancer cells. Proc. Natl. Acad. Sci. USA 95: 10,842–10, 847.Google Scholar
  87. 87.
    Partin, A. W., et al. 1997. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multiinstitutional update (published erratum appears in JAMA 1997 Jul 9; 278: 118). JAMA 277: 1445–1451.Google Scholar
  88. 88.
    Pesche, S., et al. 1998. PTEN/MMAC1/TEP1 involvement in primary prostate cancers. Oncogene 16: 2879–2883.PubMedCrossRefGoogle Scholar
  89. 89.
    Phillips, S. M., et al. 1994. Loss of the retinoblastoma susceptibility gene (RB1) is a frequent and early event in prostatic tumorigenesis. Br. J. Cancer 70: 1252–1257.PubMedCrossRefGoogle Scholar
  90. 90.
    Pilepich, M. V., et al. 1986. Adjuvant chemotherapy with adriamycin, cytoxan, and cis-platinum in high-grade carcinoma of the prostate treated with definitive radiotherapy (RTOG pilot 81–12). Am. J. Clin. Oncol. 9: 135–138.PubMedCrossRefGoogle Scholar
  91. 91.
    Pilepich, M. V., et al. 1995. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group. Urology 45: 616–623.PubMedCrossRefGoogle Scholar
  92. 92.
    Pilepich, M., et al. 1998. Phase III Radiation therapy oncology group trial 86–10 of androgen deprivation before and during radiotherapy in locally advanced carcinoma of the prostate. J. Clin. Oncol. 17 (Abstract).Google Scholar
  93. 93.
    Radford, I. R. 1986. Evidence for a general relationship between the induced level of DNA double-strand breakage and cell-killing after X-irradiation of mammalian cells. Int. J. Radiat. Biol. Relat. Stud. Phys. Chem. Med. 49: 611–620.PubMedCrossRefGoogle Scholar
  94. 94.
    Ragde, H., et al. 1998. Ten-year disease free survival after transperineal sonographyguided iodine-125 brachytherapy with or without 45-gray external beam irradiation in the treatment of patients with clinically localized, low to high Gleason grade prostate carcinoma. Cancer 83: 989–1001.PubMedCrossRefGoogle Scholar
  95. 95.
    Ripple, M. O., et al. 1997. Prooxidant-antioxidant shift induced by androgen treatment of human prostate carcinoma cells. J. Natl. Cancer Inst. 89: 40–48.PubMedCrossRefGoogle Scholar
  96. 96.
    Roentgen, W. C. 1895. Ueber eine nue Art von Strahlen. Proceedings of the Wurzburg Phisico-Medical Society, December 28.Google Scholar
  97. 97.
    Russell, K. J., et al. 1994. Photon versus fast neutron external beam radiotherapy in the treatment of locally advanced prostate cancer: results of a randomized prospective trial. Int. J. Radiat. Oncol. Biol. Phys. 28: 47–54.PubMedCrossRefGoogle Scholar
  98. 98.
    Sano, H., et al. 1995. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res. 55: 3785–3789.PubMedGoogle Scholar
  99. 99.
    Scherr, D. S., et al. 1999. BCL-2 and p53 expression in clinically localized prostate cancer predicts response to external beam radiotherapy. J. Urol. 162: 12–16 (discussion).Google Scholar
  100. 100.
    Schlicker, A., et al. 1999. 4-Amino-1,8-naphthalimide: a novel inhibitor of poly(ADPribose) polymerase and radiation sensitizer. Int. J. Radiat. Biol. 75: 91–100.Google Scholar
  101. 101.
    See, W. A., et al. 1996. Brachytherapy and continuous infusion 5-fluorouracil for treatment of locally advanced, lymph node negative, prostate cancer: a phase I trial. Cancer 77: 924–927.PubMedCrossRefGoogle Scholar
  102. 102.
    Seetharam, S., et al. 1998. Modulation of apoptotic response of a radiation-resistant human carcinoma by Pseudomonas exotoxin-chimeric protein. Cancer Res. 58: 3215–3220.PubMedGoogle Scholar
  103. 103.
    Semenza, G. L. 1998. Hypoxia-inducible factor 1 and the molecular physiology of oxygen homeostasis. J. Lab. Clin. Med. 131: 207–214.PubMedCrossRefGoogle Scholar
  104. 104.
    Shipley, W. U., et al. 1995. Advanced prostate cancer: the results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone. Int. J. Radiat. Oncol. Biol. Phys. 32: 3–12.PubMedCrossRefGoogle Scholar
  105. 105.
    Sintich, S. M., et al. 1999. Cytotoxic sensitivity to tumor necrosis factor-alpha in PC3 and LNCaP prostatic cancer cells is regulated by extracellular levels of SGP-2 (clusterin). Prostate 39: 87–93.PubMedCrossRefGoogle Scholar
  106. 106.
    Slater, J. D., et al. 1999. Conformal proton therapy for early-stage prostate cancer. Urology 53: 978–984 (discussion).Google Scholar
  107. 107.
    Slovin, S. F., et al. 1998. Interferon-gamma and monoclonal antibody 131I-labeled CC49: outcomes in patients with androgen-independent prostate cancer. Clin. Cancer Res. 4: 643–651.PubMedGoogle Scholar
  108. 108.
    Spitzweg, C., et al. 1999. Prostate-specific antigen (PSA) promoter-driven androgen-inducible expression of sodium iodide symporter in prostate cancer cell lines. Cancer Res. 59: 2136–2141.PubMedGoogle Scholar
  109. 109.
    Stackhouse, M. A., et al. 1998. Radiosensitization mediated by a transfected anti-erbB-2 single-chain antibody in vitro and in vivo. Int. J. Radiat. Oncol. Biol. Phys. 42: 817–822.PubMedCrossRefGoogle Scholar
  110. 110.
    Stattin, P., et al. 1996. Pretreatment p53 immunoreactivity does not infer radioresistance in prostate cancer patients. Int. J. Radiat. Oncol. Biol. Phys. 35: 885–889.PubMedCrossRefGoogle Scholar
  111. 111.
    Steinberg, J., et al. 1997. Intracellular levels of SGP-2 (Clusterin) correlate with tumor grade in prostate cancer. Clin. Cancer Res. 3: 1707–1711.PubMedGoogle Scholar
  112. 112.
    Sternick, E. S., ed. 1997. The Theory and Practice of Intensity Modulated Radiation Therapy. Advanced Medical Publishing: Madison, WI.Google Scholar
  113. 113.
    Stromberg, J. S., et al. 1997. Conformal high dose rate iridium-192 boost brachytherapy in locally advanced prostate cancer: superior prostate-specific antigen response compared with external beam treatment. Cancer J. Sci. Am. 3: 346–352.PubMedGoogle Scholar
  114. 114.
    Suit, H. D. 1992. Local control and patient survival. Int. J. Radiat. Oncol. Biol. Phys. 23: 653–660.PubMedCrossRefGoogle Scholar
  115. 115.
    Suzuki, H., et al. 1998. Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues. Cancer Res. 58: 204–209.PubMedGoogle Scholar
  116. 116.
    Tennant, M. K., et al. 1996. Protein and messenger ribonucleic acid (mRNA) for the type 1 insulin-like growth factor (IGF) receptor is decreased and IGF-II mRNA is increased in human prostate carcinoma compared to benign prostate epithelium. J. Clin. Endocrinol. Metab. 81: 3774–3782.PubMedCrossRefGoogle Scholar
  117. 117.
    Theodorescu, D., et al. 1997. p53, bc1–2 and retinoblastoma proteins as long-term prognostic markers in localized carcinoma of the prostate. J. Urol. 158: 131–137.Google Scholar
  118. 118.
    Turner, B. C., et al. 1997. Insulin-like growth factor-I receptor overexpression mediates cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation. Cancer Res. 57: 3079–3083.PubMedGoogle Scholar
  119. 119.
    van der Vijgh, W. J. and G. J. Peters. 1994. Protection of normal tissues from the cytotoxic effects of chemotherapy and radiation by amifostine (Ethyol): preclinical aspects. Semin. Oncol. 21 (5 Suppl. 11): 2–7.PubMedGoogle Scholar
  120. 120.
    Verhey, L. J. 1999. Comparison of three-dimensional conformal radiation therapy and intensity-modulated radiation therapy systems. Semin. Radiat. Oncol. 9: 78–98.PubMedCrossRefGoogle Scholar
  121. 121.
    Wasserman, T. H. 1994. Radiotherapeutic studies with amifostine (Ethyol). Semin. Oncol. 21 (5 Suppl. 11): 21–25.PubMedGoogle Scholar
  122. 122.
    Watson, E. R., et al. 1978. Hyperbaric oxygen and radiotherapy: a Medical Research Council trial in carcinoma of the cervix. Br. J. Radiol. 51: 879–887.PubMedCrossRefGoogle Scholar
  123. 123.
    Weidner, N., et al. 1993. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am. J. Pathol. 143: 401–409.PubMedGoogle Scholar
  124. 124.
    Whang, Y. E., et al. 1998. Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc. Natl. Acad. Sci. USA 95: 5246–5250.PubMedCrossRefGoogle Scholar
  125. 125.
    Wick, W., et al. 1999. PTEN gene transfer in human malignant glioma: sensitization to irradiation and CD95L-induced apoptosis. Oncogene 18: 3936–3943.PubMedCrossRefGoogle Scholar
  126. 126.
    Yang, C. R., et al. 1999. Isolation of Ku70-binding proteins (KUBs). Nucleic Acids Res. 27: 2165–2174.PubMedCrossRefGoogle Scholar
  127. 127.
    Young, H. H. and W. A. Frontz. 1917. Some new methods in the treatment of carcinoma of the lower genito-urinary tract with radium. J. Urol. 1: 505–541.Google Scholar
  128. 128.
    Zelefsky, M. J., et al. 1999. Long term tolerance of high dose three-dimensional conformal radiotherapy in patients with localized prostate carcinoma. Cancer 85: 2460–2468.PubMedCrossRefGoogle Scholar
  129. 129.
    Zelefsky, M. J. and W. F. Whitmore, Jr. 1997. Long-term results of retropubic permanent 125-iodine implantation of the prostate for clinically localized prostatic cancer. J. Urol. 158: 23–29; discussion 29–30.Google Scholar
  130. 130.
    Zhang, H., et al. 1999. Apoptosis induced by overexpression of hMSH2 or hMLH 1. Cancer Res. 59: 3021–3027.PubMedGoogle Scholar
  131. 131.
    Zhang, S., et al. 1998. Expression of potential target antigens for immunotherapy on primary and metastatic prostate cancers. Clin. Cancer Res. 4: 295–302.PubMedGoogle Scholar
  132. 132.
    Zietman, A. L., et al. 1997. The effect of androgen deprivation and radiation therapy on an androgen-sensitive murine tumor: an in vitro and in vivo study. Cancer J. Sci. Am. 3: 31–36.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2001

Authors and Affiliations

  • Naren R. Ramakrishna
  • Theodore L. DeWeese

There are no affiliations available

Personalised recommendations